After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...